Drug intelligence / Profile preview

MAGE-1

Development stage: Preclinical
Lead developer: Biogenea
Modality: Peptides
Administration: Injection

Overview

MAGE-1 is a tumor-associated antigen (TAA) identified in glioblastoma multiforme (GBM). It is a peptide component used in personalized neoantigenic vaccines, such as the TamavaqTM NeoVaccine, to stimulate tumor-specific T-cell reactivity and enhance tumor targeting in patients with glioma.

Targets

HLA-DRB1*15:01HLA-B7

Beyond the preview

Go deeper on MAGE-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAGE-1.

Explore the full profile